Rechercher des projets européens

12 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

mTOR pathophysiology in rare human diseases (RariTOR)

Date du début: 1 févr. 2015, Date de fin: 31 janv. 2020,

The mammalian Target Of Rapamycin (mTOR) is a master regulator of growth. mTOR is a protein kinase that exists in two distinct complexes in the cell and transduces virtually all anabolic signals from the environment: nutrients, such as glucose and amino acids, growth factor peptides, such as insulin and insulin like growth factors, oxygen, mitochondrial metabolites, energy status. mTOR is required ...
Voir le projet

 1

 TERMINÉ 

Glomerulonephritis and Focal Segmental Glomerulosclerosis as a Model to Investigate the Link between Inflammation and Kidney Disease: From Basic Mechanisms to Clinical Application (TARGET GLOMDIS)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,

"Rapidly progressive glomerulonephritis (RPGN) and focal and segmental glomerulosclerosis (FSGS) are severe kidney diseases responsible for irreversible renal failure, which is a major risk factor for mortality. Despite the aggressiveness of immunosuppressive protocols applied, treatments against RPGN have limited effectiveness. Similarly, there is no specific treatment for FSGS. We built this res ...
Voir le projet

 1

 TERMINÉ 

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Date du début: 1 mars 2011, Date de fin: 31 déc. 2017,

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Voir le projet

 10

 TERMINÉ 

Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)

Date du début: 1 oct. 2010, Date de fin: 30 sept. 2017,

Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Voir le projet

 17

 TERMINÉ 

European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet

 29

 TERMINÉ 

Development of an innovative paediatric formulation of an antiepileptic agent for the treatment of absence epilepsy in children (KIEKIDS)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2017,

The KIEKIDS project is dedicated to the development of an innovative paediatric formulation of an antiepileptic agent for a safe alternative treatment of absence epilepsy in children.Development of such an age-appropriate formulation is regarded by The European Medicines Agency (EMA) to be amongst one of highest priorities for the treatment of absence seizures, using a drug with identified and doc ...
Voir le projet

 4

 TERMINÉ 

Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)

Date du début: 1 févr. 2010, Date de fin: 30 sept. 2015,

An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Voir le projet

 23

 TERMINÉ 

Primary immunodeficiency diseases as models for the study of the immune system (PIDIMMUN)

Date du début: 1 juil. 2010, Date de fin: 30 juin 2015,

The study of primary immunodeficiency diseases has provided significant insights into how the immune system works. This notably includes in vivo immune responses to microorganisms, pathogens or opportunistic agents and in vivo control of reactivity to self, in relation to the identification of specific gene mutations. Hence, some of the key factors of the immune system have been unraveled. In this ...
Voir le projet

 1

 TERMINÉ 

The B cell memory program: cell fate determinants and functional diversity of B cell subsets (Memo-B)

Date du début: 1 juil. 2010, Date de fin: 30 juin 2015,

B cells are responsible for the humoral arm of the immune response and most successfulvaccines in humans are antibody-based. Depending on the pathogen, specific B cell subsets aremobilized and a variety of innate, intermediate or adaptive responses are produced. In somecases these responses generate memory in anticipation of a re-encounter with the same pathogen.B cells can also present antigens t ...
Voir le projet

 1

 TERMINÉ 

Impact of IL-7 and IFNa on nTreg development (3ITD)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2013,

"In developed countries, most HIV-infected patients are under highly active antiretroviral therapy (HAART). However, despite controlled viral replication, the immune reconstitution often remains incomplete, probably due to a poor reconstitution of thymic production. Apart its role in educating a diverse repertoire of conventional T-cells, the thymus also produces natural regulatory T-cells (nTreg) ...
Voir le projet

 1

 TERMINÉ 

The role of host cell actin cytoskeleton in invasion by Apicomplexa parasites (API-INVASION)

Date du début: 1 déc. 2009, Date de fin: 30 nov. 2012,

"Members of the Apicomplexa phylum are obligatory intracellular parasites many of which being important human pathogens. Plasmodium sp., the etiological agent of malaria is the most devastating but Toxoplasma gondii can be severe in both immune-compromised individuals where it causes encephalitis or pneumonia and infect fetuses. These parasites invade host cells by transforming into specialized st ...
Voir le projet

 1

 TERMINÉ 

Cell growth control by nutrients (NUTRITION)

Date du début: 1 oct. 2008, Date de fin: 30 sept. 2012,

Mammalian Target Of Rapamycin (mTOR) is an evolutionary conserved protein kinase that integrates signals from growth factors, nutrients and cellular energy status to regulate cell proliferation, survival, growth and metabolism. mTOR functions have been inferred so far by employing rapamycin, an inhibitor that has therapeutical uses as immunosuppressive and anti cancer agent. However rapamycin is n ...
Voir le projet

 1